TaiGen Biopharmaceuticals Holdings Limited Profit Margin

TaiGen Biopharmaceuticals Holdings Limited (4157.TWO) currently reports a profit margin of 60.49% as of June 2026. That compares with -595.28% in the prior-year period — up 110.2% year over year. That is above the Healthcare sector average of 21.34%. Use the charts on this page to explore TaiGen Biopharmaceuticals Holdings Limited's profit margin history and peer comparisons.

TaiGen Biopharmaceuticals Holdings Limited's profit margin increased from -595.28% to 60.49% — a 110.2% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

TaiGen Biopharmaceuticals Holdings Limited's profit margin of 60.49% is higher than the Healthcare sector average of 21.34%. That is roughly 183.5% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but TaiGen Biopharmaceuticals Holdings Limited's current 60.49% should be judged against Healthcare norms (sector average: 21.34%) and against 4157.TWO's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of 60.49%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.34%. From there, open related valuation or income-statement pages for TaiGen Biopharmaceuticals Holdings Limited, and consider following 4157.TWO for alerts when major investors trade the stock.